Transfusion Triggers In Cardiac Surgery Australia Trial (TRICS-III)
Funder
National Health and Medical Research Council
Funding Amount
$1,433,956.00
Summary
This study seeks to compare outcomes for cardiac surgery patients who are given a blood transfusion where the haemoglobin concentration is <7.5 or alternatively <9.5 g/dL. Blood transfusion is common in cardiac surgery and it is not known whether a more "restrictive" approach to blood transfusion has a different outcome. This will be the largest prospective randomised study of its kind, Australia contributing to a Canadian lead multi-centre international trial.
IV Iron For Treatment Of Anaemia Before Cardiac Surgery (ITACS Trial)
Funder
National Health and Medical Research Council
Funding Amount
$2,285,290.00
Summary
Our aim is to evaluate intravenous iron to treat anaemia in 1000 patients waiting for their cardiac surgery. This could reduce the risks of the operation and enable patients to recover faster and can go home earlier.
Does Placental Transfusion Prevent Death And Disability In Very Preterm Infants? Childhood Follow Up In The NHMRC Australian Placental Transfusion Study.
Funder
National Health and Medical Research Council
Funding Amount
$889,406.00
Summary
A million babies are born before 30 weeks gestation worldwide each year. Many die or face a lifetime of disability. Enhancing placental transfusion in these infants by deferred clamping of the umbilical cord (DCC) is a simple procedure that may reduce mortality and major disability in childhood. The Australian Placental Transfusion Study (APTS), the largest ever RCT of deferred clamping, will follow up 1200 children born preterm to evaluate if DCC has childhood benefits at 2 years age.
Understanding Tissue Responses To Fluid Resuscitation And Blood Transfusion During Ovine Sepsis To Improve Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$980,810.00
Summary
Annually, sepsis affects up to 30 million patients, killing more patients than the combined totals of breast, prostate and lung cancer. Fluid resuscitation is a cornerstone of sepsis therapy, aimed at improving oxygen delivery to key organs. Data now indicates that blood and non-blood fluids may worsen mortality. This study will investigate the mechanism of sepsis and the effect of blood and non-blood fluids, to provide data to clinicians which may reduce the vast global burden of this disease.
Trial To Evaluate Anti-fibrinolytic Therapy In Thrombocytopenia (TREATT)
Funder
National Health and Medical Research Council
Funding Amount
$1,057,478.00
Summary
Patients with haematologic malignancies often have low platelet counts from their disease or treatment. This can be associated with bleeding, which can sometimes be serious or fatal. Nearly 2/3 of all platelet transfusions in Australia are given in this setting to try to prevent bleeding but many people still experience bleeding. This study asks whether tranexamic acid can safely & effectively reduce bleeding and if it does, does reduced bleeding lead to reduction in platelet transfusions?
STandaRd Issue TrANsfusion VersuS Fresher Red Blood Cell Use In IntenSive CarE (TRANSFUSE) – A Randomised Controlled Trial.
Funder
National Health and Medical Research Council
Funding Amount
$2,890,335.00
Summary
In Australia, blood for transfusions has a “use by” date of 42 days after collection. The actual age of blood given to patients depends on what is available at the time and the rate of usage. Some research has been done to suggest it might help patients in the intensive care unit reach a better recovery if they receive blood transfusions that are younger than this. This project will test whether patients who receive ‘fresher’ blood do better than patients who receive ‘standard issue ’ blood.
Extra Corporeal Membrane Oxygenation (ECMO) is a heart/lung machine that replaces blood CO2 with oxygen, giving organs a chance to rest after injury due to infection or trauma. It saved many lives in the swine flu outbreak. Blood moving across foreign surfaces causes inflammation, cell injury and a need for transfusions. This study aims to identify which part of the ECMO causes injury and how. This will to improve survival rates of the most severe forms of cardiac and respiratory disease.
Should Very Premature Babies Receive A Placental Transfusion At Birth? A Randomised Controlled Trial.
Funder
National Health and Medical Research Council
Funding Amount
$2,875,774.00
Summary
Premature babies under 30 weeks gestation are up to a hundred times more likely than full term babies to die or survive with major disability, often from brain damage due to poor blood flow after birth. This randomised study will find out if giving them more placental blood at birth, by means of a delay in clamping the umbilical cord, then milking it, reduces anemia, blood transfusions, brain damage, infection, death and disability. The results may benefit millions of premature babies worldwide.